Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
QAB149 · 4 trials · 3 indications
IC was measured with spirometry conducted according to internationally accepted standards. Peak IC was defined as the maximum IC of the mean at one of the post-dose measurements (30min, 60min, 120min, 180min and 240min).
| Arm | Type | Description |
|---|---|---|
| Sequence A | PLACEBO_COMPARATOR | Patients will inhale QAB149 (capsule form in blister packs) + Placebo via Novartis Concept 1 SDDPI |
| Sequence B | ACTIVE_COMPARATOR | Patients will inhale QAB149 plus NVA237 (capsule form in blister packs) via Novartis Concept 1 SDDPI |
| 1 | EXPERIMENTAL | QAB149 |
| Name | Type | Description |
|---|---|---|
| QAB149 | DRUG | Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI |
| Placebo | DRUG | Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI |
| NVA237 | DRUG | Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI |
Inclusion criteria: * Male and female patients, ≥40 years of age, with a documented diagnosis of moderate or severe COPD according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and \>10-pack year history of smoking * FEV1 \<80% and ≥30% of the predicted normal value who ...
QAB149 is an investigational small molecule being studied for the treatment of chronic obstructive pulmonary disease (COPD). It is in Phase 2 clinical development and has been evaluated in dose-ranging and safety studies in patients with mild-to-moderate COPD. QAB149 is not FDA approved and remains in clinical development.
QAB149 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. Novartis has sponsored multiple clinical trials evaluating QAB149 in patients with COPD and hepatic insufficiency.
QAB149 is in Phase 2 clinical development for chronic obstructive pulmonary disease (COPD). It has completed two Phase 2 trials and one Phase 1 trial. The drug is investigational and has not been approved by regulatory authorities.
QAB149 has completed several clinical trials, including NCT00098228, a dose-ranging study in 686 patients with COPD, and NCT00129831, a safety and tolerability study in 6 patients with mild-to-moderate COPD. A Phase 1 trial, NCT00416702, assessed the drug in healthy subjects and those with impaired liver function.
Yes, QAB149 is also known as indacaterol. Clinical trial NCT00416702 is titled 'Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function,' confirming that QAB149 and indacaterol refer to the same compound.